ICS/LABA Adherence and COPD Exacerbation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02446041|
Recruitment Status : Completed
First Posted : May 15, 2015
Last Update Posted : October 11, 2016
|Condition or disease||Intervention/treatment|
|Pulmonary Disease Chronic Obstructive||Other: Non-Interventional Study|
|Study Type :||Observational|
|Actual Enrollment :||10000 participants|
|Official Title:||Adherence and COPD Exacerbation Rates in Patients Initiating ICS/LABA Therapy.|
|Study Start Date :||May 2015|
|Actual Primary Completion Date :||October 2015|
|Actual Study Completion Date :||October 2015|
ICS/LABA Patients following standard of care
Other: Non-Interventional Study
- Exacerbation rate [ Time Frame: 12 months ]Rate of COPD exacerbation occurring during the 12 months after therapy initiation.
- Severe Exacerbation rate [ Time Frame: 12 months ]Severe exacerbation rate during the 12 months after therapy initiation
- Time to Exacerbation [ Time Frame: 12 months ]Time to first COPD exacerbation during the 12 months after therapy initiation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02446041
|United States, Delaware|
|Wilmington, Delaware, United States|
|Study Chair:||Frank Trudo, MD||AstraZeneca|